Pre-Open Stock Movers 06/03: Turning Point Doubles on Takeover; Tesla Falls as Musk Worried About Economy, Cutting 10% of Staff
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Novavax (NVAX) Shares Halted for News Pending Ahead of FDA Panel
June 7, 2022 6:55 AM EDTNovavax (NASDAQ: NVAX) Shares Halted for News Pending Ahead of FDA Panel
Bristol Myers Squibb's Turning Point Offer Fair, Says Stifel
June 3, 2022 12:07 PM EDTOn Friday, it was announced that Bristol-Myers Squibb (NYSE: BMY) will acquire Turning Point Therapeutics (NASDAQ: TPTX) for $4.1 billion or $76 a share, more than double Thursday's closing price of $34.16.
Following the news, Stifel analyst Bradley Canino said the cash offer for... More
Citi Reiterates $90 PT on Bristol-Myers Squibb Co. (BMY), 'We expect some FTC scrutiny...but given the Pfizer/ Arena outcome, we remain hopeful'
June 3, 2022 11:39 AM EDTCiti analyst Andrew Baum reiterated a Buy rating and $90.00 price target on Bristol-Myers Squibb Co. (NYSE: BMY)/
The analyst comments "PFEs ability to close the Arena deal with little FTC scrutiny, coupled with biotechs de-rating has unsurprisingly re-ignited M&A momentum with... More
UPDATE: Cowen Reiterates $150 PT on Novavax (NVAX), Believes 'briefing documents suggest that the vaccine meets all the requirements for approval '
June 3, 2022 11:23 AM EDT(Updated - June 3, 2022 11:24 AM EDT)
Cowen analyst Georgi Yordanov reiterated an Outperform rating and $150.00 price target on Novavax (NASDAQ: NVAX).
The analyst comments " Overall, we believe the briefing documents suggest that the vaccine meets all the requirements for approval and we expect a positive vote at next week's meeting. As for the timing of a potential approval, the Agency does highlight that Novavax is yet to... More
